http://www.baylorclinic.com/index.cfm ® Copy Right Agradecemos al Dr. Carlos Vallbona miembro Honorífico de APPLAC, sus aportaciones sobre el tema deSíndrome de Post Polio,su ponencia fue magistral, su experiencia es extraordinaria y nos comunicoque de México tiene 2,3700 pacientes. lo que nos da una idea sí quisieramos realmente tener unaestadística, tendríamos que sumar todas las clínicas de USA donde cada médico tiene una base depacientes con SPP. ! Nos vemos en el Tercer Simposium ¡ http://www.postpolio-efectos-secundarios-del-la-polio.org/ext/http://www.baylorclinic.com/index.cfm ® Copy Right Vallbona receives clinical professionalism award HOUSTON -- (May 25, 2006) -- Dr. Carlos Vallbona, professor of family and community medicine at BCM, received the second annual Ben and Margaret Love Foundation Bobby Alford Award for Academic Clinical Professionalism.The Award recognizes a BCM physician for professionalism and humanism, and the ability to role model these qualities in the practice of medicine.Although it can be difficult to truly define professionalism, it implies that a physician is acting in the best interest of the patient and always with a commitment to excellence.Dr. Thomas Wheeler, Harlan J. Spjut professor and interim chair of pathology at BCM, nominated Vallbona for the award."Dr. Vallbona exemplifies the finest attributes of a physician and his life has served as a role model for countless numbers of house-staff and junior faculty for over four decades," said Wheeler. "In an era when medicine is considered a business and economic factors have dominance in the delivery of health care, Dr. Vallbona's exemplary life serves to remind all physicians and health care workers of our true calling."Vallbona started his career at BCM in 1955 as a third-year pediatric resident where he worked under the direction of Dr. William Spencer at the Southwestern Poliomyelitis Respiratory and Rehabilitation Center at Jeff Davis Hospital.In 1969, Vallbona became chair of community medicine and his primary responsibility was to provide medical faculty to staff the neighborhood health centers of the Harris County Hospital District. HCHD is the fourth largest public metropolitan health system and was one of the first large health systems to provide integrated primary and preventive health care to medically underserved communities. Under the leadership and vision of Vallbona, the department formed an alliance with key HCHD personnel and community physicians and created the Community Health Program.Strategizing for future-health care needs, Vallbona partnered with the staff of the City of Houston and Harris County health departments, and The University of Texas School of Public Health, to identify community health-care problems and opportunities. Under his vision, operational improvements such as the creation of a database of HCHD patient visits, and the use of a miniature credit-card-like medical record carried by patients were instituted over the years.In addition to his role with the HCHD, Vallbona also serves on the Board of Directors for Healthcare for the Homeless-Houston, a joint program of BCM and SEARCH Homeless project whose mission is to promote health, hope and dignity for Houston's homeless through accessible and comprehensive care.Any physician faculty at BCM or one of its affiliated institutions may be nominated for the award. Nominations are reviewed and a recommendation is then made by an appointed Selection Committee .www.baylorclinic.com/index.cfm
Vallbona recibe el premio profesionalidad clínicaHOUSTON - (25 de mayo 2006) - Dr. Carlos Vallbona, profesor de medicina familiar y comunitaria en el CBM, recibió el segundo Ben anuales y Margaret Love Fundación Bobby Alford Premio a la Profesionalidad Académica Clínica.El Premio reconoce a un médico BCM para el profesionalismo y el humanismo, y la capacidad de modelar el papel de estas cualidades en la práctica de la medicina.Aunque puede ser difícil de definir realmente el profesionalismo, que implica que un médico está actuando en el mejor interés del paciente y siempre con un compromiso con la excelencia.El Dr. Thomas Wheeler, profesor Harlan J. Spjut y presidente interino de la patología en el CBM, nominado para el premio Vallbona."El doctor Vallbona es un ejemplo de los mejores atributos de un médico y su vida ha servido de modelo para un número incalculable de la casa con el personal y profesorado con menos experiencia por más de cuatro décadas", dijo Wheeler. "En una era cuando la medicina se considera un negocio y los factores económicos tienen una posición dominante en la prestación de asistencia sanitaria, vida ejemplar doctor Vallbona sirve para recordar a todos los médicos y trabajadores de la salud de nuestra verdadera vocación".Vallbona comenzó su carrera en el CBM en 1955 como un residente de pediatría de tercer año, donde, bajo la dirección del Dr. William Spencer en el suroeste de Poliomielitis y respiratoria Centro de Rehabilitación en el Hospital Jeff Davis.En 1969, se convirtió en presidente de Vallbona medicina comunitaria y su objetivo primordial es el de proporcionar al personal de la facultad de medicina de los centros de salud de barrio del Harris County Hospital District. HCHD es el cuarto sistema público de salud metropolitano y fue uno de los grandes sistemas de salud integrados primera en ofrecer la atención primaria y preventiva de salud a médicos comunidades marginadas. Bajo el liderazgo y la visión de Vallbona, el departamento formó una alianza con el personal clave de HCHD y médicos de la comunidad y creó el Programa de Salud Comunitaria.Formulación de una estrategia para el futuro cuidado de la salud necesita, Vallbona se asoció con el personal de la Ciudad de Houston y el Condado de Harris departamentos de salud, y la Universidad de Texas Escuela de Salud Pública, para identificar problemas de la comunidad de atención sanitaria y oportunidades. Bajo su visión, las mejoras operativas, tales como la creación de una base de datos de visitas de pacientes HCHD, y el uso de un registro médico en miniatura de tarjetas de crédito-como el realizado por los pacientes fueron instituidos en los últimos años.Además de su rol con el HCHD, Vallbona también es miembro del Consejo de Administración de Salud para las Personas sin Hogar-Houston, un programa conjunto de BCM y SEARCH proyecto para personas sin hogar, cuya misión es promover la salud, la esperanza y dignidad para personas sin hogar en Houston a través de accesibles y atención integral.Cualquier médico de profesores en el CBM o una de las entidades afiliadas pueden ser nominados para el premio. Se revisan las nominaciones y una recomendación se hace entonces por un Comité de Selección designado. Dr. Brian Joseph Miembro Honorario de APPLAC y Liliana Marasco Garrido Canadá,Suecia y México unen lazos.
|Ernesto Maury, V.P & Co-Founder Litaff|
THE LATEST NEWS ON POST POLIO SYNDROME (PPS)
Three important issues came from this symposium; we feel it is important that we share this latest news with everyone. Some may already know there is a WHO Code for Post Polio Syndrome, that there is a possible marker waiting for approval by the ...Journal And that they are continuing to find IV Immunoglobulin is continuing to help those of us with PPS! We apologize that it has beendelayed to ill health.
Xepol® (XP-28) – Acquired by Grifols
The first medical treatment of Post-Polio SyndromeXepol is the first pharmaceutical product to address the unmet medical need of patients suffering fromPost-Polio Syndrome (PPS). Even though new infections from the poliovirus ceased in developedcountries more than 30 years ago, many patients are now struggling with renewed complicationsfrom the disease. While rarely fatal, the neurological and muscular symptoms of PPS are lifelong anddebilitating. There is no medical treatment besides physiotherapy and assistive devices. Approximately30-40% of survivors of paralytic polio develop severe PPS. There are around 300,000 PPS patients inmajor Western markets.Following a Pharmalink designed and sponsored development programme, Xepol was sold toGrifols, a group of companies which researches, develops, manufactures and markets productsserving healthcare professionals and patients in over 90 countries around the world, in June 2010.Grifols intends to bring the product to market using all acquired assets.
Product backgroundThe concept behind Xepol was first developed by Dr Henrik Gonzalez and Professor Kristian Borg, bothscientists at the Karolinska Institute (Sweden), and is backed by strong evidence suggesting an underlyingneuroinflammatory pathology. Xepol is an injectable biological product which is administeredonce every 9 – 12 months and down regulates the inflammatory process in the nervous systemof PPS patients. It was acquired by Pharmalink as an original concept backed by preliminary positiveclinical observations.Xepol is protected by patents in major markets. In addition, market exclusivity was achieved by aUS Orphan Drug Designation granted in 2006.Given the prevalence of PPS, there is the potential to achieve orphan drug designation in all major markets.
Development programme:Following positive preliminary clinical studies, Pharmalink sponsored a Phase III trial of Xepol in PPS.The trial clearly met one of its two primary endpoints, relating to muscle strength, and results were published inthe Lancet. In a follow-on study trial, still double- blinded, a defined subset of patients met both originalendpoints showing a reduction of inflammatory cytokines in the cerebrospinal fluid and a significant reductionof symptoms of PPS while also showing that Xepol is safe and well tolerated with few or no side-effects. Significant results were also shown in endpoints such as pain, walking ability and SF-36 scores. Full access to these data was a key feature of the package acquired by Grifols with its acquisition of the programme in 2010. Xepol – Pharmalink in ActionIn June 2010, Pharmalink sold all intellectual property and assets related to its Xepolprogramme, the first medical treatment for post-polio syndrome, to Grifols, a group of companieswhich researches, develops, manufactures and markets products serving healthcare professionalsand patients in over 90 countries around the world. The Xepol concept was originally developedby scientists at Karolinska Institute in Sweden. Pharmalink, following positive preliminary clinicalstudies, sponsored a Phase III of Xepol in post-polio syndrome, which demonstrated the product’spotential in the treatment of this lifelong and debilitating condition. All rights to the programme, includingaccess to the data generated by Pharmalink, have been acquired by Grifols. Grifols will develop theproduct using all acquired assets, with Pharmalink assisting in providing the company with technologytransfer and access to physician and patient organizations.PHARMALINK REPORTS POSITIVE PHASE III RESULTS FOR XEPOL®, A TREATMENT FOR POST‐ POLIO SYNDROME
The follow‐on results strengthen the position of this novel treatment modality for PPS by demonstrating a reduction ofinflammatory cytokines in the cerebrospinal fluid and a significant reduction of symptoms of PPS while also showing that Xepol®is safe and well tolerated with few or no side‐effects. Endpoints studied were pain, walking ability and SF‐36 scores (a commonself assessment scoring system that measures physical and psychological variables). All showed significant and clinically meaningfulresults. Full results are to be published in a peer review journal. Xepol®, the first medical PPS treatment , is an injectable biologic product, administered once per 9‐12 months, which down‐regulates the inflammatory process in the nervous system of PPS patients. The concept and medical hypothesis was first developedby Dr Henrik Gonzalez and Professor Kristian Borg, scientists at the Karolinska Institute (Sweden). Pharmalink licensed the invention and is now working to bring the candidate towards registration. “We are very encouraged by the outcome of the follow‐up analysis as it is clear from the results that Xepol brings relief from pain and muscle weakness to PPS patients,” said Johan Häggblad, Managing Director of Pharmalink.“We are very excited about this data as currently there is no medical treatment for PPS and patients in the treated group have experienced a reduction in disease symptoms after just 12 months.” “It is very rewarding to see that Xepol is demonstrating efficacy and the potential to help PPS patients,” said inventor and principal investigator Professor Kristian Borg. “We are looking forward to expanding the Xepol treatment procedure following product registration.” Pharmalink is actively seeking a partner to bring Xepol® to the market. More than 1000 PPS patients have been treated with the drug and many return on an annual basis for new treatment courses. Xepol® has already achieved Orphan Drug Designation in the US and is patented in the major markets.